Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer

Cancer Biology and Therapy

Volumn 10, Issue 1, 2010, Pages 13-18

  Gao, Rui ^a,b   Price, Douglas K ^a   Dahut, William L ^a   Reed, Eddie ^c   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

BER; DNA excision repair; Genetic polymorphism; Haplotype; Prostate cancer; Radiotherapy; XRCC1

Indexed keywords

MOLECULAR MARKER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADULT; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DNA REPAIR; EXCISION REPAIR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 77954415447     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.1.12172     Document Type: Article

References (33)

1. DeVita VTJL Jr, Theodore S, Steven AR, Ronald AD, Robert AW. Principles and Practice of Oncology. Lippincott Williams & Wilkins (LWW) 2008.
2. Roach M, 3rd, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009; 115:3112-20.
3. Gao R, Price DK, Sissung T, Reed E, Figg WD. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1 and PARP1. Mol Cancer Ther 2008; 7:1246-50.
4. Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 2009; 8:665-70.
5. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411:366-74.
6. Churchill ME, Peak JG, Peak MJ. Repair of near-visible-and blue-light-induced DNA single-strand breaks by the CHO cell lines AA8 and EM9. Photochem Photobiol 1991; 54:639-44.
7. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene 2006; 25:1612-9.
8. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:1513-30.
9. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 2005; 14:1810-8.
10. Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 2005; 97:567-76.
11. Tae K, Lee HS, Park BJ, Park CW, Kim KR, Cho HY, et al. Association of DNA repair gene XRCC1 polymorphisms with head and neck cancer in Korean population. Int J Cancer 2004; 111:805-8.
12. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111:1843-50.
13. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 2008; 170:49-59.
14. De Ruyck K, Van Eijkeren M, Claes K, Morthier R, De Paepe A, Vral A, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3 and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005; 62:1140-9.
15. Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von Fournier D, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1 and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005; 11:4802-9.
16. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006; 65:646-55.
17. Brem R, Cox DG, Chapot B, Moullan N, Romestaing P, Gerard JP, et al. The XRCC1-77T->C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 2006; 27:2469-74.
18. Yoon SM, Hong YC, Park HJ, Lee JE, Kim SY, Kim JH, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63:885-91.
19. Wang XG, Wang ZQ, Tong WM, Shen Y. PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem Biophys Res Commun 2007; 354:122-6.
20. Ben-Hur E. Involvement of poly (ADP-ribose) in the radiation response of mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med 1984; 46:659-71. (Pubitemid 15169368)
21. Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, Sebolt-Leopold JS. Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-rayinduced cellular recovery processes in Chinese hamster V79 cells. Radiat Res 1991; 126:367-71.
22. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998; 78:1269-77. (Pubitemid 28495236)
23. van Duin M, de Wit J, Odijk H, Westerveld A, Yasui A, Koken HM, et al. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986; 44:913-23. (Pubitemid 16045337)
24. van Duin M, Koken MH, van den Tol J, ten Dijke P, Odijk H, Westerveld A, et al. Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res 1987; 15:9195-213.
25. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993; 365:852-5.
26. Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, et al. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology 2007; 70:217-20.
27. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52:1855-65.
28. Levy N, Martz A, Bresson A, Spenlehauer C, de Murcia G, Menissier-de Murcia J. XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage. Nucleic Acids Res 2006; 34:32-41. (Pubitemid 43160033)
29. Monaco R, Rosal R, Dolan MA, Pincus MR, Brandt-Rauf PW. Conformational Effects of a Common Codon 399 Polymorphism on the BRCT1 Domain of the XRCC1 Protein. Protein J 2007.
30. Hu JJ, Smith TR, Miller MS, Lohman K, Case LD. Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ Mol Mutagen 2002; 39:208-15.
31. Marintchev A, Robertson A, Dimitriadis EK, Prasad R, Wilson SH, Mullen GP. Domain specific interaction in the XRCC1-DNA polymerase beta complex. Nucleic Acids Res 2000; 28:2049-59. (Pubitemid 30255525)
32. Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003; 12:1168-74. (Pubitemid 37499439)
33. Azria D, Ozsahin M, Kramar A, Peters S, Atencio DP, Crompton NE, et al. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 2008; 14:6284-8.